The 43 percent reduction in the mortality rate in the group given isosorbide dinitrate plus hydralazine occurred among patients who
Isosorbide dinitrate is a medication used for heart failure, esophageal spasms, and to treat and prevent chest pain from not enough blood flow to the heart
Isosorbide dinitrate: Metabolized extensively; about 15–25 and 75–85% of a dose is metabolized to isosorbide-2-mononitrate and isosorbide-5-mononitrate (referred to
Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine–isosorbide dinitrate arm (25 percent) (P = 0
Active-controlled Study: In a second study of mortality, V-HeFT II, the combination of hydralazine and isosorbide dinitrate 75 mg/40 mg 4 times daily was compared to enalapril in 804 men with impaired cardiac function and reduced exercise tolerance (NYHA class II and III), and on therapy with digitalis glycosides and diuretics
Isosorbide dinitrate lacks a large randomized study to delineate the ideal drug-free interval
Dengan penggunaan yang tepat, isosorbide dinitrate dapat mencegah dan mengatasi angina, serta mengobati gagal jantung
These headaches may gradually become less severe as you continue to use nitroglycerin
Lower mortality in Enalapril group due to lower incidence of
Combination of isosorbide dinitrate and hydralazine recommended by ACCF and AHA for self-identified black patients with NYHA class III or IV heart failure and reduced ejection fraction who NO homeostasis may be reset with combination therapy with isosorbide dinitrate (ISD), an NO donor, and hydralazine (HY) to prevent tachyphylaxis to the nitrate compound (11,12)
6 The corresponding 95% confi-dence interval indicates that isosorbide dinitrate use could be associated with anywhere between a 0
2 The efficacy of hydralazine-isosorbide dinitrate (H-ISDN) therapy for heart failure (HF) was established in the first Vasodilator-Heart Failure Trial (V-HeFT I), The mortality benefits observed were not as robust as those observed in the A-HeFT trial
The effectiveness of H-ISDN in clinical practice is unknown The combination of hydralazine–isosorbide dinitrate (H-ISDN) has potential as a heart failure (HF) therapy in the setting of maintenance dialysis
10 Although the mortality benefit was superior with enalapril, isosorbide dinitrate–hydralazine induced greater improvements in ejection fraction and exercise tolerance